| First Author | Demeyer A | Year | 2020 |
| Journal | iScience | Volume | 23 |
| Issue | 10 | Pages | 101557 |
| PubMed ID | 33083726 | Mgi Jnum | J:305935 |
| Mgi Id | MGI:6705923 | Doi | 10.1016/j.isci.2020.101557 |
| Citation | Demeyer A, et al. (2020) Long-Term MALT1 Inhibition in Adult Mice Without Severe Systemic Autoimmunity. iScience 23(10):101557 |
| abstractText | The protease MALT1 is a key regulator of NF-kappaB signaling and a novel therapeutic target in autoimmunity and cancer. Initial enthusiasm supported by preclinical results with MALT1 inhibitors was tempered by studies showing that germline MALT1 protease inactivation in mice results in reduced regulatory T cells and lethal multi-organ inflammation due to expansion of IFN-gamma-producing T cells. However, we show that long-term MALT1 inactivation, starting in adulthood, is not associated with severe systemic inflammation, despite reduced regulatory T cells. In contrast, IL-2-, TNF-, and IFN-gamma-producing CD4(+) T cells were strongly reduced. Limited formation of tertiary lymphoid structures was detectable in lungs and stomach, which did not affect overall health. Our data illustrate that MALT1 inhibition in prenatal or adult life has a different outcome and that long-term MALT1 inhibition in adulthood is not associated with severe side effects. |
